Comparing the Clinical Effectiveness of High-Dose and Low-Dose Statin Therapy in Patients with Atherosclerotic Coronary Artery Disease (CAD)
Clinical Effectiveness of High-Dose and Low-Dose Statin Therapy in Atherosclerotic Disease
DOI:
https://doi.org/10.54393/pjhs.v5i10.1993Keywords:
High Dose, Statin Therapy, Low-Density Lipoprotein Cholesterol, Artery DiseasesAbstract
Coronary artery disease is associated with the circulatory system and leading cause of death around the globe, Objective: To compare the mean changes in low-density lipoprotein cholesterol with high and low doses of statin therapy. Methods: A non-randomized controlled trial at the Department of Cardiology, Fauji Foundation Hospital Rawalpindi was conducted from January 26-2023 to July 25-2023, among patients aged 45-75 years of both genders with ST-elevation myocardial infarction or non-ST-elevation myocardial infarction. Patients were divided into groups using a convenience sampling technique. Patients in Group A were given high-dose statin therapy atorvastatin 40mg orally daily. While Group B received low-dose statin therapy atorvastatin 20mg orally daily. The low-density lipoprotein cholesterol level was repeated after 3 months. Data were entered and analyzed using SPSS version 23. Results: The mean age of Group A was 56.14 ± 8.9 years and Group B was 57.5 ± 9.7 years, as per gender distribution group A showed 57.1% and Group B 68.6%, whereas, the females in Group A, were calculated as 42.9% and in Group B 31.4%. The mean changes observed in low-density lipoprotein cholesterol were significantly higher in groups in comparison to the group with low-dose statin therapy. The changes observed were significant at 35 ± 27.8mg/dl in higher statin therapy versus 21.4 ± 20 mg/dl with a p-value of 0.024. Conclusions: It was concluded that high-dose statin causes a greater reduction in low-density lipoprotein cholesterol levels. The high-dose therapy could be a great option in treating the low-density lipoprotein in initial management.
References
Ishii J, Kashiwabara K, Ozaki Y, Takahashi H, Kitagawa F, Nishimura H et al. Small Dense Low-Density Lipoprotein Cholesterol and Cardiovascular Risk in Statin-Treated Patients with Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis. 2022 Oct; 29(10): 1458-74. doi: 10.5551/jat.63229.
Hodkinson A, Tsimpida D, Kontopantelis E, Rutter MK, Mamas MA, Panagioti M. Comparative Effectiveness of Statins on Non-High Density Lipoprotein Cholesterol in People with Diabetes and at Risk of Cardiovascular Disease: Systematic Review and Network Meta-Analysis. British Medical Journal. 2022 Mar; 376. doi: 10.1136/bmj-2021-067731.
Sulehria SB and Athar CA. Comparative Effectiveness of Atorvastatin (Low Vs High Dose) in Lowering Low-Density Lipoprotein Cholesterol in Intermediate Risk Cardiovascular Patients. Pakistan Journal of Medical & Health Sciences. 2020 Jun; 14(2): 2020312.
Roy D, Mahapatra T, Manna K, Kar A, Rana MS, Roy A et al. Comparing the Effectiveness of High-Dose Atorvastatin and Rosuvastatin among Patients Undergone Percutaneous Coronary Interventions: A non-Concurrent Cohort Study in India. Plos One. 2020 May; 15(5): e0233230. doi: 10.1371/journal.pone.0233230.
Higuma T, Akashi YJ, Fukumoto Y, Obara H, Kakuma T, Asaumi Y et al. Residual Coronary Risk Factors Associated With Long-Term Clinical Outcomes in Patients With Coronary Artery Disease Treated With High Vs. Low-Dose Statin Therapy―REAL-CAD Sub-study. Circulation Journal. 2024 May; 88(6): 995-1003. doi: 10.1253/circj.CJ-23-0134.
Chen PY, Liu YH, Duan CY, Fan HL, Zeng LH, Guo W et al. Association of In-Hospital Intensive Statins Dosage and Death in Arteriosclerotic Cardiovascular Disease With Percutaneous Coronary Intervention: Insights of Multicentre Cohort from China. European Journal of Clinical Pharmacology. 2020 Dec; 76: 1755-63. doi: 10.1007/s00228-020-02966-1.
Yamaji T, Harada T, Kajikawa M, Maruhashi T, Kishimoto S, Yusoff FM et al. Role of Small Dense Low-density Lipoprotein Cholesterol in Cardiovascular Events in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Receiving Statin Treatment. Journal of Atherosclerosis and Thrombosis. 2024 Apr; 31(4): 478-500. doi: 10.5551/jat.64416.
Higashioka M, Sakata S, Honda T, Hata J, Shibata M, Yoshida D et al. The Association of Small Dense Low-Density Lipoprotein Cholesterol and Coronary Heart Disease in Subjects at High Cardiovascular Risk. Journal of Atherosclerosis and Thrombosis. 2021 Jan; 28(1): 79-89. doi: 10.5551/jat.55350.
Huang J, Gu JX, Bao HZ, Li SS, Yao XQ, Yang M et al. Elevated Serum Small Dense Low‐Density Lipoprotein Cholesterol May Increase the Risk and Severity of Coronary Heart Disease and Predict Cardiovascular Events in Patients with Type 2 Diabetes Mellitus. Disease Markers. 2021; 2021(1): 5597028. doi: 10.1155/2021/5597028.
Campos H, Moye LA, Glasser SP, Stampfer MJ, Sacks FM. Low-Density Lipoprotein Size, Pravastatin Treatment, and Coronary Events. Journal of the American Medical Association. 2001 Sep; 286(12): 1468-74. doi: 10.1001/jama.286.12.1468.
Wang X and Ji X. Sample Size Estimation in Clinical Research: From Randomized Controlled Trials to Observational Studies. Chest. 2020 Jul; 158(1): S12-20. doi: 10.1016/j.chest.2020.03.010.
Nishikura T, Koba S, Yokota Y, Hirano T, Tsunoda F, Shoji M et al. Elevated Small Dense Low-Density Lipoprotein Cholesterol as a Predictor for Future Cardiovascular Events in Patients with Stable Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis. 2014 Aug; 21(8): 755-67. doi: 10.5551/jat.23465.
Bytyçi I, Shenouda R, Wester P, Henein MY. Carotid Atherosclerosis in Predicting Coronary Artery Disease: A Systematic Review and Meta-Analysis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2021 Apr; 41(4): e224-37. doi: 10.1161/ATVBAHA.120.315747.
Barter PJ. High-Versus Low-Dose Statin: Effects on Cardiovascular Events and All-Cause Death. Circulation. 2018 May; 137(19): 2013-5. doi: 10.1161/CIRCULATIONAHA.118.034407.
Bergström G, Persson M, Adiels M, Björnson E, Bonander C, Ahlström H et al. Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population. Circulation. 2021 Sep; 144(12): 916-29. doi: 10.1161/CIRCULATIONAHA.121.055340.
Liu D, Du C, Shao W, Ma G. Diagnostic Role of Carotid Intima‐Media Thickness for Coronary Artery Disease: A Meta‐Analysis. Biomed Research International. 2020; 2020(1): 9879463. doi: 10.1155/2020/9879463.
Migliorino D, Mignano A, Evola S, Polizzi G, Novo G, Corrado E et al. Correlation Between Carotid Atherosclerosis and Coronary Artery Disease: A Retrospective Study of 1067 Patients. Nutrition, Metabolism and Cardiovascular Diseases. 2017 Jan; 27(1): e28. doi: 10.1016/j.numecd.2016.11.077.
Maqsood M, Sadeeqa S, Ahmad M, Afzal H. Efficacy and Safety of Atorvastatin and Rosuvastatin in Ischemic Heart Disease Patients: A Prospective Study. Tropical Journal of Pharmaceutical Research. 2019; 18(7): 1533-8. doi: 10.4314/tjpr.v18i7.25.
Priti K, Agrawal A, Ranwa BL. High Versus Low Dose Statin Therapy in Indian Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Thrombolysis. Indian Heart Journal. 2017 Jul; 69(4): 453-7. doi: 10.1016/j.ihj.2017.05.026.
Zahid R, Asif HM, Tanveer R, Summar Z, Najib M. Recommended Guidelines and Efficacy of Statins in Case of Hyperlipidemia. RADS Journal of Pharmacy and Pharmaceutical Sciences. 2021; 9(4): 231-7.
Javed MA, Adnan F, Bukhari SN, Zaffar Z, Abid MS, Zarif A. Effectiveness of High Dose Statins among Acute Coronary Syndrome Patients Presenting at a Tertiary Care Hospital. In Medical Forum Monthly. 2021; 32(4).
Hameed I, Shah SA, Aijaz A, Mushahid H, Farhan SH, Dada M et al. Comparative Safety and Efficacy of Low/Moderate-Intensity Statin plus Ezetimibe Combination Therapy vs. High-Intensity Statin Monotherapy in Patients with Atherosclerotic Cardiovascular Disease: An Updated Meta-Analysis. American Journal of Cardiovascular Drugs. 2024 May; 24(3): 419-31. doi: 10.1007/s40256-024-00642-8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments